The recent decision by the National Institute of Health and Care Excellence (NICE) to reject two Alzheimer’s drugs on the basis of “not providing good value for money” was met with considerable disappointment.  Pharmaceutical company Eisai, developer of the rejected therapy lecanemab, was understandably disappointed , saying it was “deeply concerned” by the decision, questioning […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!